within Pharmacolibrary.Drugs.ATC.S;

model S01XA27
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 150000000000.0 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01XA27</td></tr><td>route:</td><td>subretinal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Voretigene neparvovec is a gene therapy product used for the treatment of inherited retinal dystrophy due to confirmed biallelic RPE65 mutations, approved for use in several regions including the US and EU. It delivers a functional copy of the RPE65 gene via an adeno-associated virus vector to retinal cells to improve vision.</p><h4>Pharmacokinetics</h4><p>No traditional pharmacokinetic parameters (such as plasma concentration profiles) are reported, as voretigene neparvovec is a gene therapy vector administered directly into the subretinal space, with primarily local retinal action and minimal systemic distribution. Clinical pharmacokinetic studies are not applicable.</p><h4>References</h4><ol><li><p>Ciulla, TA, et al., &amp; Nagiel, A (2020). Voretigene neparvovec-rzyl for treatment of . <i>Expert opinion on biological therapy</i> 20(6) 565–578. DOI:<a href=&quot;https://doi.org/10.1080/14712598.2020.1740676&quot;>10.1080/14712598.2020.1740676</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32149547/&quot;>https://pubmed.ncbi.nlm.nih.gov/32149547</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01XA27;
